Remove 2012 Remove Competition Remove Leads
article thumbnail

Understanding the evidence used in drug product withdrawals

European Pharmaceutical Review

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 Lane S, Lynn E, Shakir S.

Medicine 116
article thumbnail

It’s time for more tech and biotech innovation in 2023

pharmaphorum

The drive to make the UK a ‘scientific powerhouse’ was central to the government’s announcement closing out 2022 , which appointed five industry experts to lead on the sectors most vital to UK’s future innovation. Since co-founding Benchling in 2012, Ashu has overseen the company’s rapid growth. About the author.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 14 Marketing authorisation In the UK, medicinal products placed on the market are required to have marketing authorisations in accordance with The Human Medicines Regulations 2012 (S.I. 2012/1916).

Marketing 103
article thumbnail

Global comparator data signal “alarm bells” for UK Government, says APBI

pharmaphorum

Latest UK Life Sciences Competitive Indicators “ought to ring alarm bells across Government,” says ABPI. Richard Torbett, chief executive at the Association of the British Pharmaceutical Industry (ABPI) said Life Sciences Competitive Indicators (LSCI) data published last week “ought to ring alarm bells across Government”.

article thumbnail

The EU HTA regulation: a new frontier for access to innovative technologies

European Pharmaceutical Review

Article 15 proved that transparent and effective assessments of new technologies were crucial to ensure fair competition between stakeholders that operate in the EU. In addition, he was Head of the Legal Service at the European Medicines Agency from 2004 to 2012. effectiveness and therapeutic efficacy.

article thumbnail

The Fastest Growing Companies in Boston Hiring For Sales

CloserIQ

Founded 2012. Founded 2012. They’ve worked with leading clients such as Twitter and Mercedes Benz. Founded 2012. Founded 2012. Founded 2012. They are seeking to transform the automobile industry and are known for a fast-paced, collaborative work environment. ProfitWell. 11-50 employees. $10 See open roles.

Sales 76
article thumbnail

How to Adapt Your Marketing Now That Private Practice Has Become an “Endangered Species”

Healthcare Success

Here’s a brief timeline: In 2012, 60.1% This step is particularly crucial in an era where new competition enters the market every day. One of the best ways to do this is through competitive analysis. ” “What are their leading products and services? By 2018, that percentage had fallen to 54%.